{
    "clinical_study": {
        "@rank": "122870", 
        "arm_group": [
            {
                "arm_group_label": "Insulin detemir + metformin + diet/exercise", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin NPH + metformin + diet/exercise", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted globally. The aim of the trial is to investigate the efficacy and\n      safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination\n      with metformin and diet/exercise on glycaemic control in children and adolescents with type\n      2 diabetes insufficiently controlled on metformin with or without other oral antidiabetic\n      drug(s) with or without basal insulin."
        }, 
        "brief_title": "A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent from the subject or a legally acceptable representative (LAR) and\n             child assent from the subject obtained before any trial-related\n             activities.Trial-related activities are any procedures that are carried out as part\n             of the trial, including activities to determine suitability for the trial\n\n          -  Male or female, above or equal to 10 years and below or equal to 17 years at the time\n             of signing informed consent/assent\n\n          -  Diagnosis of type 2 diabetes mellitus at least 3 months prior to screening\n\n          -  Treated with a stable dose of metformin (1000-2000 mg/day) for at least 3 months\n             prior to screening with or without other OAD(s) with or without basal insulin\n\n          -  HbA1c (glycosylated haemoglobin) above or equal to 7.0% and below or equal to 10.5%\n             (above or equal to 53 mmol/mol and below or equal to 91 mmol/mol) at screening\n\n        Exclusion Criteria:\n\n          -  Maturity onset diabetes of the young (MODY)\n\n          -  Fasting C-peptide at screening below 0.6 ng/mL\n\n          -  Impaired liver function defined as alanine aminotransferase (ALT) above or equal to\n             2.5 times upper normal limit\n\n          -  Known proliferative retinopathy or maculopathy requiring acute treatment as judged by\n             the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "358", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131272", 
            "org_study_id": "NN304-4093", 
            "secondary_id": [
                "2013-005500-33", 
                "U1111-1151-4056"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin detemir + metformin + diet/exercise", 
                "description": "Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial metformin treatment should continue unchanged during the treatment period.", 
                "intervention_name": "insulin detemir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin NPH + metformin + diet/exercise", 
                "description": "Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial metformin treatment should continue unchanged during the treatment period.", 
                "intervention_name": "insulin NPH", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Hypoglycemic Agents", 
                "Insulin, NPH", 
                "Metformin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 13, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Las Vegas", 
                    "country": "United States", 
                    "state": "Nevada", 
                    "zip": "89148"
                }, 
                "name": "Novo Nordisk Clinical Trial Call Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin \u00b1 Other Oral Antidiabetic Drug(s) \u00b1 Basal Insulin", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Brazil: National Health Surveillance Agency", 
                "Canada: Public Health Agency of Canada", 
                "China: Food and Drug Administration", 
                "Croatia: Ministry of Health and Social Care", 
                "Denmark: Danish Medicines Agency", 
                "France: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Greece: National Organization of Medicines", 
                "Hungary: National Institute of Pharmacy", 
                "India: Ministry of Health", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy: National Institute of Health", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Macedonia, The Former Yugoslav Republic of: Ministry of Health", 
                "Malaysia: Ministry of Health", 
                "Mexico: National Institute of Public Health, Health Secretariat", 
                "Netherlands: Dutch Health Care Inspectorate", 
                "Poland: Ministry of Health", 
                "Russia: Pharmacological Committee, Ministry of Health", 
                "Serbia: Agency for Drugs and Medicinal Devices", 
                "South Africa: Medicines Control Council", 
                "Spain: Ministry of Health", 
                "Taiwan: Department of Health", 
                "Turkey: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c (glycosylated haemoglobin)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, Week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131272"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in body weight standard deviation score (SDS)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, Week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving HbA1c below 7.0%, who have not experienced any treatment emergent severe hypoglycaemic episodes within the last 14 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "At week 26"
            }, 
            {
                "measure": "Proportion of subjects achieving HbA1c below 7.5%,  who have not experienced any treatment emergent severe hypoglycaemic episodes within the last 14 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "At Week 26"
            }, 
            {
                "measure": "Total number of treatment emergent nocturnal (23:00-06:59) severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 - 26"
            }, 
            {
                "measure": "Total number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 - 26"
            }, 
            {
                "measure": "Incidence of adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 - 26"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}